Using Real World Data to Individualize HCV Management

Volume 5, Issue 8.

In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Clinical Insights: HCV and Substance Use Disorder

Volume 5, Issue 6.

This podcast, Andrew H. Talal, MD, MPH and Richard Blondell, MD from the University at Buffalo discuss expanding HCV screening in persons with substance abuse disorders.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.